Telemetry Investments, L.L.C. Humanigen, Inc Transaction History

Telemetry Investments, L.L.C.

$63.3 Million
Q4 2022

A detailed history of Telemetry Investments, L.L.C. transactions in Humanigen, Inc stock. As of the latest transaction made, Telemetry Investments, L.L.C. holds 470,000 shares of HGEN stock, worth $0. This represents 0.09% of its overall portfolio holdings.

Number of Shares

470,000

Previous 500,000 6.0%

Holding current value

Previous $90,000 37.78%

% of portfolio

0.09%

Previous 0.12%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.09 - $0.2 $2,700 - $6,000	-30,000 Reduced 6.0%	470,000 $56,000
Q3 2022 Nov 17, 2022	BUY	$0.15 - $3.02 $64,050 - $1.29 Million	427,000 Added 584.93%	500,000 $90,000
Q2 2022 Aug 15, 2022	BUY	$1.76 - $3.33 $11,440 - $21,645	6,500 Added 9.77%	73,000 $129,000
Q1 2022 May 16, 2022	SELL	$1.81 - $3.97 $57,920 - $127,040	-32,000 Reduced 32.49%	66,500 $200,000
Q4 2021 Feb 14, 2022	BUY	$3.66 - $8.22 $173,850 - $390,450	47,500 Added 93.14%	98,500 $366,000
Q3 2021 Nov 15, 2021	BUY	$5.93 - $17.83 $2,959 - $8,897	499 Added 0.99%	51,000 $302,000
Q2 2021 Aug 16, 2021	SELL	$13.54 - $22.74 $324,499 - $544,986	-23,966 Reduced 32.18%	50,501 $878,000
Q1 2021 May 17, 2021	BUY	$12.91 - $23.83 $348,285 - $642,885	26,978 Added 56.81%	74,467 $1.42 Million
Q4 2020 Feb 16, 2021	SELL	$7.97 - $21.66 $750,670 - $2.04 Million	-94,187 Reduced 66.48%	47,489 $831,000
Q3 2020 Nov 16, 2020	BUY	$8.0 - $28.5 $1.13 Million - $4.04 Million	141,676 New	141,676 $1.51 Million

Others Institutions Holding HGEN

# of Institutions

Shares Held

558K

Call Options Held

Put Options Held

View Full List

About HUMANIGEN, INC

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

More about HGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Telemetry Investments, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Telemetry Investments, L.L.C. with notifications on news.

Account

Telemetry Investments, L.L.C. Humanigen, Inc Transaction History